Medicaid: What to Watch in 2022
As 2022 kicks off, a number of issues are at play that could affect coverage and financing under Medicaid. This issue brief examines key issues to watch in Medicaid in the year ahead.
View the Latest: Build Back Better
Filter
-
-
Millions of Medicare Beneficiaries Use Prescription Drugs That Could Be Subject to Price Negotiation, But Build Back Better Act Provision Exempts Many Drugs With High Federal Spending
News ReleaseTwenty drugs and dozens of insulin products used by 8.5 million Medicare beneficiaries would be subject to government drug price negotiation if the Build Back Better Act (BBBA) were enacted and fully implemented in 2022, according to a new KFF analysis.
-
New KFF Resource Explains Key Provisions for Maternal Health Within the Build Back Better Act
News ReleaseIf passed, the Build Back Better Act (BBBA) would include several provisions to improve maternal health, particularly for people of color. A new KFF Policy Watch explains the different provisions, their potential impact on parents and children, as well as the projected federal costs of these proposals.
-
How Build Back Better Would Affect Drug Costs
FeatureProvisions in the bill that would lower prescription drug costs and reduce federal drug spending would take effect over the next several years, starting in 2023.
-
Medicaid Outpatient Prescription Drug Trends During the COVID-19 Pandemic
Issue BriefThis data note describes Medicaid prescription drug utilization and spending trends in calendar year 2020 compared to previous years to explore how the pandemic impacted Medicaid prescription drug utilization and spending.
-
Community Health Centers in the U.S. Territories and the Freely Associated States
Issue BriefThe U.S territories and the Freely Associated States (FAS) have faced an array of longstanding fiscal and health challenges, made worse by recent natural disasters and the coronavirus pandemic. Community health centers are an important part of health care system in the territories and FAS, providing access to a range of primary care services to low-income and vulnerable individuals. Based on findings from a survey of health centers, data from the Uniform Data System (UDS), and interviews with Primary Care Associations in those regions, this brief examines the roles of health centers in U.S. territories and FAS during the COVID-19 pandemic.
-
Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act
Issue BriefThe Build Back Better Act (BBBA) includes a range of health and other proposals supported by President Biden, including a proposal to allow the federal government to negotiate the price of some prescription drugs covered under Medicare Part B (administered by physicians) and Medicare Part D (retail outpatient drugs). This brief illustrates the potential scope of the drug price negotiation proposal in the BBBA. This analysis is designed to highlight the types of Medicare-covered drugs that could be subject to negotiation, and which of the current top-spending drugs covered by Part B and Part D could be subject to price negotiation, and in what years, if the BBBA is enacted.
-
Public Health Infrastructure and Pandemic Preparedness Provisions in the Build Back Better Act
Issue BriefThis brief summarizes funding for public health infrastructure as well as pandemic preparedness as specified in the Build Back Better Act introduced in the House.
-
Summary of Costs and Impact of the Prescription Drug Provisions in the Build Back Better Act
News ReleaseAs the House-passed Build Back Better Act moves to the Senate, a new explainer from KFF summarizes the key prescription drug provisions within the broader budget reconciliation bill. These provisions would lower prescription drug costs paid by people with Medicare and private insurance and curb drug spending by the federal government and private payers.
-
Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
Event Date:EventAs the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs.